医学
蛋白尿
内科学
肾病
抗体
膜性肾病
免疫学
内分泌学
肾
糖尿病
作者
Sean J. Barbour,Fernando C. Fervenza,Dilshani Induruwage,Paul Brenchley,Brad H. Rovin,Michelle Hladunewich,Heather N. Reich,Richard A. Lafayette,Nabeel Aslam,Gerald B. Appel,Ladan Zand,Krzysztof Kiryluk,Lili Liu,Daniel Cattran
出处
期刊：Clinical Journal of The American Society of Nephrology
[American Society of Nephrology]
日期：2023-07-20
卷期号：18 (10): 1283-1293
被引量：13
标识
DOI：10.2215/cjn.0000000000000237
摘要
The 2021 Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend following anti-phospholipase A2 receptor (PLA2R) antibody levels as a marker of treatment response in membranous nephropathy; however, the optimal timing to evaluate antibody levels and how to combine them with other clinical variables are currently unknown.
科研通智能强力驱动
Strongly Powered by AbleSci AI
YifanWang
浅尝离白
shinysparrow
寻道图强
sutharsons
70
穆紫
杳鸢
Magali
sunny
随机子
共享精神
积极慕梅
大模型
SciGPT
梁朝伟
misha991
空气狗
科研張
Singularity
皖公网安备34019202002308
